candesartan has been researched along with Renal Insufficiency, Chronic in 10 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to investigate whether withaferin A treatment ameliorates the development of renal fibrosis and its related mechanisms in a CKD mouse model." | 7.96 | Withaferin A protects against endoplasmic reticulum stress-associated apoptosis, inflammation, and fibrosis in the kidney of a mouse model of unilateral ureteral obstruction. ( Chen, CM; Chiang, CK; Chung, YP; Guan, SS; Huang, KT; Liu, CH; Liu, SH; Wu, CT, 2020) |
| "Elastin deficiency causes vascular stiffening, a leading risk for hypertension and chronic kidney disease (CKD)." | 7.85 | Elastin insufficiency causes hypertension, structural defects and abnormal remodeling of renal vascular signaling. ( Jie, L; Osei-Owusu, P; Owens, EA; Reyes, BAS; Van Bockstaele, EJ, 2017) |
| "Azilsartan is a strong antihypertensive ARB, but its antiproteinuric effects are not well understood." | 7.01 | Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial. ( Eriguchi, M; Fujisaki, K; Kitazono, T; Nakano, T; Suehiro, T; Tanaka, S; Torisu, K; Tsuchimoto, A; Tsujikawa, H; Tsuruya, K; Yamada, S; Yoshida, H, 2021) |
| "We aimed to investigate whether withaferin A treatment ameliorates the development of renal fibrosis and its related mechanisms in a CKD mouse model." | 3.96 | Withaferin A protects against endoplasmic reticulum stress-associated apoptosis, inflammation, and fibrosis in the kidney of a mouse model of unilateral ureteral obstruction. ( Chen, CM; Chiang, CK; Chung, YP; Guan, SS; Huang, KT; Liu, CH; Liu, SH; Wu, CT, 2020) |
| "Elastin deficiency causes vascular stiffening, a leading risk for hypertension and chronic kidney disease (CKD)." | 3.85 | Elastin insufficiency causes hypertension, structural defects and abnormal remodeling of renal vascular signaling. ( Jie, L; Osei-Owusu, P; Owens, EA; Reyes, BAS; Van Bockstaele, EJ, 2017) |
| "Azilsartan is a strong antihypertensive ARB, but its antiproteinuric effects are not well understood." | 3.01 | Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial. ( Eriguchi, M; Fujisaki, K; Kitazono, T; Nakano, T; Suehiro, T; Tanaka, S; Torisu, K; Tsuchimoto, A; Tsujikawa, H; Tsuruya, K; Yamada, S; Yoshida, H, 2021) |
| " Candesartan in combination with RDN prolonged trough BP and attenuated renal hemodynamic responses to blood loss." | 1.72 | Renal Denervation in Combination With Angiotensin Receptor Blockade Prolongs Blood Pressure Trough During Hemorrhage. ( Booth, LC; Denton, KM; Head, GA; May, CN; McArdle, Z; Moritz, KM; Schlaich, MP; Singh, RR, 2022) |
| "The metabolic syndrome is a risk factor for the development of chronic kidney disease." | 1.35 | Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet. ( Haruna, Y; Kashihara, N; Kobayashi, S; Komai, N; Namikoshi, T; Sasaki, T; Satoh, M; Tomita, N, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, RR | 1 |
| McArdle, Z | 1 |
| Booth, LC | 1 |
| May, CN | 1 |
| Head, GA | 1 |
| Moritz, KM | 1 |
| Schlaich, MP | 1 |
| Denton, KM | 1 |
| Yamamura-Miyazaki, N | 1 |
| Michigami, T | 1 |
| Satomura, K | 1 |
| Urushihara, M | 1 |
| Kagami, S | 1 |
| Yamamoto, K | 1 |
| Chen, CM | 1 |
| Chung, YP | 1 |
| Liu, CH | 1 |
| Huang, KT | 1 |
| Guan, SS | 1 |
| Chiang, CK | 1 |
| Wu, CT | 1 |
| Liu, SH | 1 |
| Suehiro, T | 1 |
| Tsuruya, K | 2 |
| Yoshida, H | 2 |
| Tsujikawa, H | 1 |
| Yamada, S | 1 |
| Tanaka, S | 1 |
| Tsuchimoto, A | 1 |
| Eriguchi, M | 1 |
| Fujisaki, K | 1 |
| Torisu, K | 1 |
| Nakano, T | 1 |
| Kitazono, T | 1 |
| Owens, EA | 1 |
| Jie, L | 1 |
| Reyes, BAS | 1 |
| Van Bockstaele, EJ | 1 |
| Osei-Owusu, P | 1 |
| Cechova, S | 1 |
| Dong, F | 1 |
| Chan, F | 1 |
| Kelley, MJ | 1 |
| Ruiz, P | 1 |
| Le, TH | 1 |
| Kato, H | 1 |
| Shiraishi, T | 1 |
| Ueda, S | 1 |
| Kubo, E | 1 |
| Shima, T | 1 |
| Nagura, M | 1 |
| Yano, H | 1 |
| Izumikawa, Y | 1 |
| Shimada, M | 1 |
| Tomioka, S | 1 |
| Nosaka, H | 1 |
| Kojima, K | 1 |
| Tanemoto, M | 1 |
| Uchida, S | 1 |
| Namikoshi, T | 1 |
| Tomita, N | 1 |
| Satoh, M | 1 |
| Haruna, Y | 1 |
| Kobayashi, S | 1 |
| Komai, N | 1 |
| Sasaki, T | 1 |
| Kashihara, N | 1 |
| Frimodt-Møller, M | 1 |
| Kamper, AL | 1 |
| Strandgaard, S | 1 |
| Kreiner, S | 1 |
| Nielsen, AH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study[NCT00235287] | Phase 4 | 60 participants (Anticipated) | Interventional | 2005-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for candesartan and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Antineoplastic Combined Chemotherapy Protocols; Benzimidazo | 2021 |
Beneficial effects on arterial stiffness and pulse-wave reflection of combined enalapril and candesartan in chronic kidney disease--a randomized trial.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biph | 2012 |
8 other studies available for candesartan and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Renal Denervation in Combination With Angiotensin Receptor Blockade Prolongs Blood Pressure Trough During Hemorrhage.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2022 |
Reduction in urinary angiotensinogen levels and improvement of proteinuria by renin-angiotensin system blockade in pediatric chronic kidney disease patients with very low birth weight.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Benzimidazoles; Biomarkers; Bi | 2020 |
Withaferin A protects against endoplasmic reticulum stress-associated apoptosis, inflammation, and fibrosis in the kidney of a mouse model of unilateral ureteral obstruction.
Topics: Animals; Apoptosis; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Endoplasmic Reticulu | 2020 |
Elastin insufficiency causes hypertension, structural defects and abnormal remodeling of renal vascular signaling.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2017 |
Topics: Actins; Albuminuria; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Comp | 2018 |
Brain Atrophy and Cognitive Impairment in Chronic Kidney Disease.
Topics: Animals; Atrophy; Benzimidazoles; Biphenyl Compounds; Brain; Cognitive Dysfunction; Cyclic N-Oxides; | 2018 |
Blood pressure control and satisfaction of hypertensive patients following a switch to combined drugs of an angiotensin receptor blocker and a calcium channel blocker in clinical practice of nephrology.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Azetidinecarboxylic Acid; Benzimidazoles; Benzoa | 2015 |
Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dietary Protei | 2008 |